Physician profile
Monnieque Singleton
NPI 1336193713
$17,415.99
in general payments reported to CMS, 2019-2025
55 companies · $1,448 in 2025
The $1,448 reported for 2025 was more than what 92% of Family Medicine providers received nationally (typical 2025 total: $153).
Payments by year
General and research payments by program year, as reported to CMS.
General payments by year: 2019: $4,930 · 2020: $4,094 · 2021: $2,045 · 2022: $1,626 · 2023: $1,759 · 2024: $1,514 · 2025: $1,448.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $4,711 · Education: $10.38.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $4,710.65 |
| Education | $10.38 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Research payments are listed separately below. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $4,481.32 | 2019-2025 | Rybelsus, Ozempic, Wegovy |
| Novartis Pharmaceuticals Corporation | $2,912.64 | 2019-2025 | |
| Astrazeneca Pharmaceuticals Lp | $1,815.92 | 2019-2025 | Farxiga, Breztri, Airsupra |
| Lilly USA, LLC | $956.75 | 2019-2025 | Mounjaro, Jardiance, Zepbound |
| Boehringer Ingelheim Pharmaceuticals, INC. | $692.59 | 2019-2025 | Jardiance, Synjardy |
| Merck Sharp & Dohme LLC | $662.38 | 2019-2025 | Verquvo, Belsomra, Steglatro |
| Bayer Healthcare Pharmaceuticals INC. | $662.29 | 2021-2025 | |
| Janssen Pharmaceuticals, INC | $580.43 | 2019-2023 | Xarelto |
| Glaxosmithkline, LLC. | $472.03 | 2019-2025 | Trelegy Ellipta, Arexvy, Shingrix |
| Sanofi-Aventis U.S. LLC | $449.50 | 2019-2023 | |
| Takeda Pharmaceuticals U.S.A., INC. | $369.48 | 2019-2023 | Trintellix |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $364.15 | 2020-2024 | Xifaxan, Trulance |
| Pfizer INC. | $339.03 | 2019-2025 | |
| Abbott Laboratories | $253.47 | 2021-2025 | Freestyle Libre 3 |
| Corcept Therapeutics | $243.66 | 2024-2025 | Korlym |
Show all 55 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astellas Pharma US INC | $164.02 | 2020-2025 | Veozah |
| Arbor Pharmaceuticals, INC. | $153.60 | 2019-2021 | |
| Abbvie INC. | $127.68 | 2021-2024 | Viberzi, Dalvance |
| Abiomed | $127.21 | 2024 | Impella |
| Vanda Pharmaceuticals INC. | $121.26 | 2022-2023 | Hetlioz |
| Esperion Therapeutics, INC. | $114.21 | 2020-2022 | |
| Amgen INC. | $103.74 | 2019-2025 | Otezla, Repatha |
| Eisai INC. | $99.06 | 2020-2021 | |
| Corvista Health, INC. | $82.06 | 2025 | Corvista System |
| Welch Allyn | $64.38 | 2021 | |
| Baxter Healthcare | $64.38 | 2022 | |
| Xeris Pharmaceuticals, INC. | $60.63 | 2022 | |
| Dexcom, INC. | $54.75 | 2021-2024 | Dexcom G6 Transmitter |
| Biohaven Pharmaceutical Holding Company Ltd. | $54.62 | 2022 | |
| Kowa Pharmaceuticals America, INC. | $53.55 | 2021-2025 | Zoryve |
| Lexicon Pharmaceuticals, INC. | $53.42 | 2023-2024 | Inpefa |
| Otsuka America Pharmaceutical, INC. | $52.97 | 2022-2023 | Rexulti |
| Genentech USA, INC. | $46.54 | 2020-2021 | |
| Indivior INC. | $39.70 | 2019-2025 | Sublocade |
| Ironwood Pharmaceuticals, INC | $39.03 | 2021-2022 | |
| Allergan, INC. | $38.28 | 2019-2020 | |
| Hikma Pharmaceuticals USA | $32.87 | 2019-2022 | |
| Ardelyx, INC. | $31.78 | 2025 | Ibsrela |
| Insulet Corporation | $29.27 | 2021 | |
| Sumitomo Pharma America, INC. | $28.97 | 2025 | Gemtesa |
| Optinose US, INC. | $28.74 | 2019 | |
| Horizon Therapeutics Plc | $28.48 | 2019-2021 | |
| Shire North American Group INC | $26.81 | 2019 | |
| Daiichi Sankyo INC. | $26.73 | 2023 | Injectafer |
| Amarin Pharma, INC. | $26.48 | 2019-2021 | |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $25.30 | 2022 | |
| Novavax INC | $24.11 | 2023 | Novavax Covid-19 Vaccine, Adjuvanted |
| Seqirus USA INC | $21.66 | 2024 | Flucelvax |
| Scpharmaceuticals INC. | $19.54 | 2025 | |
| Exact Sciences Corporation | $19.51 | 2025 | Cologuard Collection Kit |
| Verona Pharma, INC. | $17.63 | 2025 | Ohtuvayre |
| Edwards Lifesciences Corporation | $16.58 | 2021 | |
| Philips North America LLC | $14.81 | 2019 | |
| Opko Pharmaceuticals, LLC | $14.69 | 2019 | |
| Mylan Specialty L.P. | $11.30 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
Research and ownership
$150.00 in research payments reported 2019-2025. Research payments are often institution-directed and tied to clinical trials: they are reported under a clinician's name but frequently go to a hospital or research organization, and usually reflect participation in medical research.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Monnieque Singleton listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.